ライフサイエンスコーパス: apnea

1 cofactors of interest (e.g., age, sex, sleep apnea).

2 physiological variation in obstructive sleep apnea.

3 ting a severe condition of obstructive sleep apnea.

4 ogonadism, intellectual disability and sleep apnea.

5 on, hyperlipidemia, venous stasis, and sleep apnea.

6 s of fictive swallow but not swallow-related apnea.

7 ay be partially explained by untreated sleep apnea.

8 alues between 90-110 s following the surface apnea.

9 n and strengthened the PCF 5-HT(3)R-mediated apnea.

10 nisms for potentially lethal seizure-related apnea.

11 breathing in the case of hypoventilation or apnea.

12 ed HF patients with moderate-to-severe sleep apnea.

13 ssary for most patients with suspected sleep apnea.

14 increased gray matter with obstructive sleep apnea.

15 body (CB) activity may be a driver of sleep apnea.

16 itive consequences seen in obstructive sleep apnea.

17 a presymptomatic stage of obstructive sleep apnea.

18 inspiratory frequency and inhibition causes apnea.

19 guously to distinguish the severity of sleep apnea.

20 d by severe bradycardia and life-threatening apneas.

21 x >/=25kg/m(2) (+1 point), obstructive sleep apnea (+1 point), gastroesophageal reflux (+1 point), an

22 9% of patients have insomnia, 25% have sleep apnea, 28% have hypersomnia, and 4% have narcolepsy.

23 lood carbon dioxide levels, as seen in sleep apnea [3].

24 post-tussive vomiting (58.1% vs. 47.9%) and apnea (37.3% vs. 29.0%); however, differences were not s

25 OHS and coexistent severe obstructive sleep apnea, 4) patients hospitalized with respiratory failure

26 e, reminiscent of clinical findings in sleep apnea [5, 6].

27 a prospective study of 74,543 cases of sleep apnea (60,125 outpatient, 14,418 inpatient) from the Swe

28 total of 268 patients with obstructive sleep apnea (75% male; mean age, 52 yr; apnea-hypopnea index,

29 19.5%), dyslipidemia (14.0%-6.8%), and sleep apnea (9.6%-2.6%) was reduced.

30 cal to the pathogenesis of obstructive sleep apnea, a common and serious sleep-related breathing diso

31 ed HF patients with moderate-to-severe sleep apnea, adding ASV to OMT did not improve 6-month cardiov

32 ography and associated conditions, including apnea and (adeno)tonsillectomy.

33 We found a link between obstructive sleep apnea and an elevated risk of stage 3 CKD or higher, but

34 es the respiratory phenotype of PWS (central apnea and blunted response to respiratory challenges).

35 prolongs superior laryngeal C-fiber-mediated apnea and bradycardia through enhancing neuronal TRPV1 e

36 is capable of aggravating the SLCF-mediated apnea and bradycardia through TRPV1 sensitization and ne

37 s that PNE would aggravate the SLCF-mediated apnea and bradycardia via up-regulating TRPV1 expression

38 dence that addresses the links between sleep apnea and cardiovascular disease, and research that has

39 ical bases for considering obstructive sleep apnea and central sleep apnea associated with Cheyne-Sto

40 ven the high prevalence of obstructive sleep apnea and CKD among adults, further investigation is war

41 iness in participants with obstructive sleep apnea and excessive sleepiness; most adverse events were

42 fibers (SLCFs) could induce bradycardia and apnea and has been implicated in SIDS pathogenesis, how

43 th medical management, reduced the number of apnea and hypopnea events and patient-reported sleepines

44 apnea-hypopnea index (AHI; ie, the number of apnea and hypopnea events/h; 15-30 indicates moderate an

45 ), exhibit sleep apnea characterized by high apnea and hypopnea indices during rapid eye movement (RE

46 into medullary respiratory centers initiated apnea and hypoxia rather than vice versa Fatal outcome w

47 ctors included sleep disturbances (eg, sleep apnea and insomnia), mental health status (eg, posttraum

48 und The autonomic nervous system response to apnea and its mechanistic connection to atrial fibrillat

49 r, increased arousals in patients with sleep apnea and other disorders prevent restful sleep and cont

50 We evaluated associations between sleep apnea and receipt of a disability pension and mortality

51 aimed to delineate the autonomic response to apnea and to test the effects of ablation of cardiac sen

52 iratory phenotype including hypoventilation, apnea, and a diminished ventilatory response to CO(2).

53 gh altitude, lung disease, obstructive sleep apnea, and age-related CNS ischemia/hypoxia, our finding

54 rom altitude sickness to airway obstruction, apnea, and atelectasis.

55 astimulation were assessed before and during apnea, and before and after intrapericardial RTX adminis

56 tension, dyslipidemia, depression, and sleep apnea, and changes in corresponding laboratory data were

57 besity, diabetes mellitus, obstructive sleep apnea, and elevated blood pressure predispose to AF, and

58 piratory obstructive disease (COPD), asthma, apnea, and others for timely and objective approaches fo

59 disorders (e.g., insomnia, obstructive sleep apnea, and parasomnias).

60 een male participants with obstructive sleep apnea (apnea-hypopnea index > 5 events/hr) were administ

61 betes, hypertension, dyslipidemia, and sleep apnea, are very common in the United States, but current

62 ng obstructive sleep apnea and central sleep apnea associated with Cheyne-Stokes respiration as poten

63 Central sleep apnea associated with Cheyne-Stokes respiration predicts

64 prevalence of obstructive and central sleep apnea associated with Cheyne-Stokes respiration.

65 ifestyle behaviors, severe obstructive sleep apnea associated with increased risk of CKD (hazard rati

66 stroke volume (SV) during voluntary surface apneas at rest up to 255 s, and during recovery from apn

67 COPD undergo screening for obstructive sleep apnea before initiation of long-term NIV (conditional re

68 ior right GP were obtained before and during apnea, before and after RTX injection in the anterior ri

69 eft atrial and ventricular remodeling, sleep apnea, blood pressure, and improved glycemic control, al

70 ngation of bronchopulmonary C-fiber-mediated apnea by prenatal nicotinic exposure in rat pups: role o

71 sive mechanical ventilation to treat central apnea (CA) occurring at night ("sleep apnea") in patient

72 nale: Primary treatment of obstructive sleep apnea can be accompanied by a persistence of excessive s

73 STATEMENT Individuals with obstructive sleep apnea can breathe adequately when awake but experience r

74 omitant procedures, diabetes mellitus, sleep apnea, cardiopathy, renal insufficiency, inflammatory bo

75 pans diabetes, renal disease, obesity, sleep apnea, cardiovascular disease, and cognitive disorders,

76 RATIONALE: Obstructive sleep apnea causes intermittent hypoxemia, hemodynamic fluctua

77 molecule carbon monoxide (CO), exhibit sleep apnea characterized by high apnea and hypopnea indices d

78 ctive sleep apnea, elevation of CO(2) during apneas contributes to awakening and restoring airway pat

79 sease, aortic aneurysm, Down syndrome, sleep apnea, depression, hyperlipidemia, astigmatism, and myop

80 disease, hyperlipidemia, hypertension, sleep apnea, diabetes mellitus, heart failure, peripheral vasc

81 ncluding obesity, physical inactivity, sleep apnea, diabetes mellitus, hypertension, and other modifi

82 diagnoses including obesity, alcohol, sleep apnea, diabetes, chronic obstructive pulmonary disease,

83 insomnia diagnosis and 3.0% reported a sleep apnea diagnosis.

84 ent fatal ictal apnea.SIGNIFICANCE STATEMENT Apnea during and following seizures is common, but also

85 During obstructive sleep apnea, elevation of CO(2) during apneas contributes to a

86 WP can detect sleep apnea events in patients with AF.

87 IGNIFICANCE STATEMENT Individuals with sleep apnea experience periods of intermittent hypoxia (IH) th

88 a result individuals with obstructive sleep apnea experience repeated episodes of upper airway closu

89 oautonomic dysfunction (neonatal bradycardia/apnea, feeding problems, hyperactive startle reflex), se

90 ent option for snoring and obstructive sleep apnea for almost three decades.

91 with developments in the treatment of sleep apnea, have accumulated in recent years.

92 d was strongest in those with moderate sleep apnea (hazard ratio, 1.59; 95% confidence interval, 1.11

93 ors that included obesity, obstructive sleep apnea, higher comorbidity, and use of prescription opioi

94 wn to be accurate for the diagnosis of sleep apnea; however, studies using the WatchPAT device have t

95 e significantly more common, including sleep apnea, hypercholesterolemia, obesity, indicators of past

96 re was a significant correlation between the apnea hypopnea index (AHI) measured by polysomnography a

97 ure mapping on three primary OSA traits [the apnea hypopnea index (AHI), overnight average oxyhemoglo

98 us mean diffusivity correlated with a higher apnea hypopnea index (Spearman's r = -0.50, p = 0.008) a

99 irway collapsibility, including the hypopnea/apnea + hypopnea ratio and the degree of flow reduction

100 demonstrations, abnormal breath conditions (apnea, hypopnea, polypnea) and the asymmetric breath con

101 Patients with upright CSR had the greatest apnea-hypopnea and central apnea index (at daytime and n

102 e participants with obstructive sleep apnea (apnea-hypopnea index > 5 events/hr) were administered an

103 with paroxysmal AF (43 with >/=moderate OSA [apnea-hypopnea index >/=15] and 43 without OSA [apnea-hy

104 To evaluate the presence of OSA (apnea-hypopnea index >= 15 events . h(-1)), all patients

105 .Methods: Data from 1,207 patients with OSA (apnea-hypopnea index >= 15 events/h) were used to evalua

106 The presence of SDB (defined as apnea-hypopnea index >=15/h) was assessed with a portabl

107 When compared with individuals without OSA (apnea-hypopnea index < 5), significantly increased risk

108 ea-hypopnea index >/=15] and 43 without OSA [apnea-hypopnea index <5]), right atrial and left atrial

109 of portable monitors, or association between apnea-hypopnea index (AHI) and health outcomes among com

110 moderate to severe SDB, defined as having an Apnea-Hypopnea Index (AHI) greater than 15 as assessed b

111 nography study that obtained measurements of apnea-hypopnea index (AHI), peripheral oxygen saturation

112 es included oxygen desaturation index (ODI), apnea-hypopnea index (AHI), subjective sleepiness (Epwor

113 e sleep apnea (OSA) have been defined by the apnea-hypopnea index (AHI).

114 e changes would correlate with reductions in apnea-hypopnea index (AHI).Methods: A total of 67 indivi

115 OSA severity was defined by the apnea-hypopnea index (AHI): severe >30, moderate >15-30,

116 Primary outcome measures were the apnea-hypopnea index (AHI; ie, the number of apnea and h

117 We used the apnea-hypopnea index (events per hour) to define obstruc

118 aphic factors (mean age, 63 yr; 52% female), apnea-hypopnea index (mean, 13.8; SD, 15.0), smoking, an

119 associated with significant improvements in apnea-hypopnea index (P < 0.001); microarousal index (P

120 idal carbon dioxide were determinants of the apnea-hypopnea index (P value range = 0.04-0.001).

121 antimuscarinic (oxybutynin) on OSA severity (apnea-hypopnea index [AHI]; primary outcome) and geniogl

122 was observed between either the obstructive apnea-hypopnea index and any aggregation parameter, but

123 on was used to model the association between apnea-hypopnea index and echocardiographic measures whil

124 Mean number of events measured by the apnea-hypopnea index decreased from 35.7/h to 2.1/h at 6

125 The apnea-hypopnea index does not capture the range of physi

126 leep-disordered breathing was ascertained by apnea-hypopnea index or clinical diagnosis.

127 Each 10-unit increase in apnea-hypopnea index was associated with 0.2 (95% CI, 0.

128 e, diabetes mellitus, and creatinine levels, apnea-hypopnea index was independently associated with i

129 raphy to determine SDB severity (obstructive apnea-hypopnea index).

130 Seventy-one subjects (ages, 55-76 yr; apnea-hypopnea index, 0.2-96.6 events/h) were evaluated

131 tive sleep apnea (75% male; mean age, 52 yr; apnea-hypopnea index, 49/h; baseline sleepiness score, 1

132 Home sleep testing was used to measure the apnea-hypopnea index, a measure of SDB severity.

133 of sleep time with oxygen saturation < 90%, apnea-hypopnea index, and oxygen desaturation index-did

134 for mortality, but its diagnostic metric-the apnea-hypopnea index-is a poor risk predictor.

135 tional oxygen desaturation indices (ODI) and apnea-hypopnea indices (AHI) according to two different

136 s the interactions between obstructive sleep apnea-hypopnea syndrome (OSAHS) and cardiovascular disea

137 generated health data, an obstructive sleep apnea-hypopnea syndrome (OSAHS) monitoring and intervent

138 However, apnea/hypopnea incidence was similarly increased in both

139 classified based on conventionally accepted apnea/hypopnea index thresholds: >=5.0/h (OSA(>=5)), >=1

140 t rest up to 255 s, and during recovery from apnea in 11 adult bottlenose dolphins (Tursiops truncatu

141 channel, non-selective (Nalcn) causes lethal apnea in humans and mice, we investigated Nalcn function

142 Early diagnosis and treatment of sleep apnea in patients with atrial fibrillation (AF) is criti

143 ry C-fibers (PCFs) and prolongs PCF-mediated apnea in rat pups, contributing to the pathogenesis of s

144 Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure) trial results.

145 a prerequisite for brainstem seizure-related apnea in this animal model and has translational value f

146 d soon after birth; surviving mice developed apneas in adulthood.

147 on of CSE with l-propargyl glycine prevented apneas in both HO-2(-/-) mice and SH rats.

148 of SERT activity is sufficient to cause the apneas in Necdin-KO pups, and that fluoxetine may offer

149 entral apnea (CA) occurring at night ("sleep apnea") in patients with systolic heart failure (HF) hav

150 Results Apnea increased anterior right GP activity, followed by

151 Conclusions Apnea increases GP activity, followed by vagal bursts an

152 had the greatest apnea-hypopnea and central apnea index (at daytime and nighttime), the worst hemody

153 and 5.3, respectively; all p < 0.05; central apnea index [CAI] of </>/=10 events/h; log-rank 8.9, 11.

154 irection, preceding local tissue hypoxia and apnea, indicating that invasion of SD into medullary res

155 Sensory neurons play a role in apnea-induced AF.

156 Apnea-induced effective refractory period shortening fro

157 Sleep apnea is a common problem affecting daily functioning an

158 Obstructive sleep apnea is a risk factor for mortality, but its diagnostic

159 al research indicates that obstructive sleep apnea is associated with increases in the incidence and

160 Seizure-related apnea is common and can be lethal.

161 Sleep apnea is common in hospitalized heart failure (HF) patie

162 Sleep apnea is highly prevalent in patients with cardiovascula

163 y behaving SUDEP-prone transgenic mice, that apnea is induced when spontaneous brainstem seizure-rela

164 circuitry that mediates arousal during sleep apnea is not known.

165 0) typically found with hypoxia during sleep apnea, M94I resulted in 37% reduction in peak INa compar

166 Obstructive sleep apnea may be associated with development of CKD through

167 Obstructive sleep apnea may be associated with preclinical thinning of the

168 ote pulmonary 5-HT secretion and prolong the apnea mediated by 5-HT(3)Rs in PCFs via affecting the 5-

169 In summary, PNE prolongs the apnea mediated by 5-HT(3)Rs in PCFs, likely by increasin

170 ion of the peak wave compared to baseline or apnea, no wave for 10 seconds) (Study group, n = 55), or

171 Apnea occurred more than hypopnea (p < 0.0001).

172 the most significant risk factors were sleep apnea (odds ratio [OR], 3.80; 95% CI, 1.00-14.49; P = .0

173 Caffeine therapy for apnea of prematurity did not significantly reduce the co

174 randomized, placebo-controlled Caffeine for Apnea of Prematurity trial between October 11, 1999, and

175 ne citrate or placebo until drug therapy for apnea of prematurity was no longer needed.

176 Children enrolled in the CAP (Caffeine for Apnea of Prematurity) randomized controlled trial and as

177 Individuals with sleep apnea often exhibit changes in cognitive behaviors consi

178 poxia (IH), a principal consequence of sleep apnea, on hippocampal adult neurogenesis remains unclear

179 ND uvul*) OR (LAUP) OR (LAVP) OR (laser AND (apnea OR apnoea OR sleep))).

180 er weaning from supplemental oxygen or flow, apnea or cyanosis during the present illness, neurologic

181 tension, emerging risk factors such as sleep apnea or inflammation, and increasingly well-defined gen

182 ted with birth weight, difficulty breathing, apnea or upper or lower respiratory infection through 8

183 confidence interval (CI): 2.58-3.53], sleep apnea (OR 1.49; 95% CI: 1.41-1.58), psychological disord

184 ears or older (OR, 1.4; P < .001), and sleep apnea (OR, 1.3; P < .001).

185 following: CHA2DS2-VASc score of >/=2, sleep apnea, or body mass index >30 kg/m(2).

186 chological issues, asthma, obstructive sleep apnea, orthopedic problems, and adverse cardiovascular a

187 Obstructive sleep apnea (OSA) affects 17% of women and 34% of men in the U

188 Obstructive sleep apnea (OSA) and asthma are highly prevalent chronic resp

189 oxia (IH) in patients with obstructive sleep apnea (OSA) and cutaneous melanoma (CM).

190 l factors is important for obstructive sleep apnea (OSA) evaluation.

191 ive pulmonary disease, and obstructive sleep apnea (OSA) exhibit daily variance.

192 A high prevalence of obstructive sleep apnea (OSA) has been reported in Down syndrome (DS) owin

193 between periodontitis and obstructive sleep apnea (OSA) has been suggested.

194 e presence and severity of obstructive sleep apnea (OSA) have been defined by the apnea-hypopnea inde

195 An adverse role for obstructive sleep apnea (OSA) in cancer epidemiology and outcomes has rece

196 s, estimated prevalence of obstructive sleep apnea (OSA) in the United States is 10% for mild OSA and

197 Obstructive sleep apnea (OSA) increases risk of dementia, a relationship t

198 We determine whether obstructive sleep apnea (OSA) increases serum levels of active TGF-beta1 i

199 Obstructive sleep apnea (OSA) is a common disorder associated with increas

200 Obstructive sleep apnea (OSA) is a common sleep disorder associated with o

201 Obstructive sleep apnea (OSA) is a highly prevalent disorder also involvin

202 Obstructive sleep apnea (OSA) is a very prevalent disorder.

203 Obstructive sleep apnea (OSA) is associated with atrial remodeling, atrial

204 Rationale: Obstructive sleep apnea (OSA) is associated with increased cardiovascular

205 Obstructive sleep apnea (OSA) is associated with systemic hypertension.

206 ies have demonstrated that obstructive sleep apnea (OSA) is associated with the development and evolu

207 Obstructive sleep apnea (OSA) is linked to increased glaucoma risk in midd

208 raphy (PSG) for diagnosing obstructive sleep apnea (OSA) is unclear.

209 Obstructive sleep apnea (OSA) is very common but is frequently undiagnosed

210 ial hypertension (ICH) and obstructive sleep apnea (OSA) on optic nerve function in children with cra

211 EI) in moderate and severe obstructive sleep apnea (OSA) patients requires elucidation.

212 Many adults with obstructive sleep apnea (OSA) use device treatments inadequately and remai

213 Moderate or severe obstructive sleep apnea (OSA) was defined as a respiratory event index >=1

214 hallmark manifestation of obstructive sleep apnea (OSA), a widespread disorder of breathing.

215 me (RLS), 21 patients with obstructive sleep apnea (OSA), and 19 healthy volunteers).

216 floppy eyelid syndrome and obstructive sleep apnea (OSA), the diagnostic criteria of floppy eyelid sy

217 tom of both narcolepsy and obstructive sleep apnea (OSA).

218 rmacological treatment for obstructive sleep apnea (OSA).

219 n samples of patients with obstructive sleep apnea (OSA).

220 aliber and the severity of obstructive sleep apnea (OSA).

221 tcomes are associated with obstructive sleep apnea (OSA).

222 ith high and low risks for obstructive sleep apnea (OSA).

223 linked to the severity of obstructive sleep apnea (OSA).

224 tical pathology underlying obstructive sleep apnea (OSA).

225 he primary risk factor for obstructive sleep apnea (OSA).

226 onic insomnia disorder and obstructive sleep apnea (OSA).

227 ed the association between obstructive sleep apnea, other sleep characteristics, and risk of incident

228 rovement in ACT scores was obstructive sleep apnea (P = 0.016).

229 definitions for positional obstructive sleep apnea (POSA).

230 the screening accuracy of the multivariable apnea prediction score followed by home portable monitor

231 hol diagnosis, diabetes, hypertension, sleep apnea, prior MI and IHD (all P<0.001) as well as AF, str

232 The sleep apnea questionnaire is an easy method of identifying the

233 isorders such as insomnia, obstructive sleep apnea, rapid eye movement sleep behavior disorder, and c

234 of men and 21% of women with inpatient sleep apnea received a disability pension.

235 ts with moderate to severe obstructive sleep apnea refusing continuous positive airway pressure treat

236 trating the role of sensory neurons in sleep apnea-related atrial fibrillation and the association be

237 well as a significantly higher rate of sleep apnea remission (72.5% vs 49.3%, P < .001) and higher sa

238 ardiovascular disease, and obstructive sleep apnea, resulting in significant health care resource use

239 .5, 99% confidence interval (CI): 1.5, 1.6), apnea (RR = 5.8, 99% CI: 5.1, 6.5), asphyxia (RR = 8.5,

240 sympathetic and GP nerve activity, abolishes apnea's electrophysiological response, and AF inducibili

241 acteristics and markers of obstructive sleep apnea severity (hypoxemia, respiratory disturbances, and

242 events per hour) to define obstructive sleep apnea severity (normal, <5.0; mild, 5.0-14.9; moderate,

243 so explored if LG and AT are correlated with apnea severity and indices of upper airway collapsibilit

244 ereafter, loop gain and measures of arousal, apnea severity and upper airway collapsibility were asce

245 stigate whether markers of obstructive sleep apnea severity are associated with gray matter changes a

246 are positively associated with loop gain and apnea severity during NREM sleep.

247 ssion was used to estimate obstructive sleep apnea severity with risk of incident CKD, adjusting for

248 eporting any insomnia symptoms, having sleep apnea, sex, body mass index, smoking status, Short Form-

249 ance abuse, age 65 years or older, and sleep apnea should be preassessed and used to help guide intra

250 veloping strategies that prevent fatal ictal apnea.SIGNIFICANCE STATEMENT Apnea during and following

251 e and behavioral deficits occurring in sleep apnea.SIGNIFICANCE STATEMENT Individuals with sleep apne

252 , OSA(>=15), and OSA(>=30) was similar to No-Apnea, STOP-Bang or NoSAS.

253 ce with other well-validated instruments: No-Apnea, STOP-Bang, and NoSAS.

254 ry of fever, or severe respiratory symptoms [apnea, stridor, nasal flaring, wheezing, chest indrawing

255 ts (N=913) underwent an in-home Type 3 sleep apnea study, clinic BP measurements, and anthropometry.

256 emature infants after caffeine treatment for apnea suggests that caffeine may protect against ROP.

257 in patients with intermediate-to-high sleep apnea suspicion (most patients requiring a sleep study).

258 Sequentially screened patients with sleep apnea suspicion were randomized to respiratory polygraph

259 he Epworth Sleepiness Scale (ESS), the Sleep Apnea Symptoms Questionnaire (SASQ), continuous positive

260 Obstructive sleep apnea syndrome (OSAS) represents a substantial disease o

261 patients with concomitant obstructive sleep apnea syndrome (OSAS) seems to have a favorable impact o

262 primary snoring through to obstructive sleep apnea syndrome (OSAS), may cause compromise of respirato

263 ypertension, diabetes, and obstructive sleep apnea syndrome between September 2007 and July 2017.

264 ody mass index [BMI] >35), obstructive sleep apnea syndrome, or other causes of respiratory failure.

265 migraine, hypotension, and obstructive sleep apnea syndrome.

266 cs with moderate to severe obstructive sleep apnea syndrome.

267 ommon disabling symptom in obstructive sleep apnea syndrome.Objectives: To evaluate the efficacy and

268 dered breathing study including a home sleep apnea test (ApneaLink Plus).

269 In recent years, a strategy of home sleep apnea testing followed by initiation of autotitrating co

270 tients, OSA can be diagnosed with home sleep apnea testing, which has a sensitivity of approximately

271 were edited to simulate Level III home sleep apnea tests (HSAT) with the auto-scored AHI and ODI base

272 During the apnea the f(H), SV, and CO decreased proportionally with

273 s review, we discuss the mechanisms of sleep apnea, the evidence that addresses the links between sle

274 Furthermore, effectiveness of sleep apnea treatment is limited by poor adherence.

275 earch that has addressed the effect of sleep apnea treatment on cardiovascular disease and clinical e

276 y, we review the recent development in sleep apnea treatment options, with special consideration of t

277 tive sleep apnea with current or prior sleep apnea treatment.

278 lethal seizures in animal models, initiates apnea upon invasion of brainstem respiratory centers.

279 ocardial ischemia and periods of respiratory apnea using a readily available mobile platform.

280 onin, or 5-hydroxytryptamine (5-HT), induces apnea via acting on 5-HT receptor 3 (5-HT(3)R) in PCFs,

281 evokes a coordinated airway defense program-apnea, vocal fold adduction, swallowing, and expiratory

282 Prevalence of severe obstructive sleep apnea was 51% (95% confidence interval, 34-69) in patien

283 Outpatient sleep apnea was associated with a higher risk of receiving a d

284 Apnea was induced by stopping ventilation until oxygen s

285 fidence interval: 0.22, 0.33 hrs), but sleep apnea was not significantly associated with diary-questi

286 OHS and coexistent severe obstructive sleep apnea), we compared the effectiveness of three years of

287 ganglion activity and blood pressure during apnea were abolished, effective refractory period increa

288 ls tested whether insomnia symptoms or sleep apnea were associated with diary-questionnaire differenc

289 riencing pneumonia, pneumothorax, sepsis, or apnea were clinical determinants of poor outcomes.

290 betes, hypertension, dyslipidemia, and sleep apnea were found to be significantly associated with ban

291 talized with HF and moderate-to-severe sleep apnea were randomized to ASV plus optimized medical ther

292 ity should be screened for obstructive sleep apnea, which is often undiagnosed and can result in poor

293 Sleep apnea, which is the periodic cessation of breathing duri

294 eptor antagonists prevented medullary SD and apnea, which may be of translational value.

295 d memantine prevented seizure-related SD and apnea, which supports brainstem SD as a prerequisite for

296 here were no associations of inpatient sleep apnea with cancer mortality.

297 iness in participants with obstructive sleep apnea with current or prior sleep apnea treatment.

298 dence supports a causal association of sleep apnea with the incidence and morbidity of hypertension,

299 We investigated the association of sleep apnea with uncontrolled BP and resistant hypertension in

300 the RR and TV estimation algorithms detected apnea within 7.9 +/- 1.1 sec and 5.5 +/- 2.2 sec, respec